CLINICAL_TRIALS
trial_result
· 2015-10-02
Clinical Trial Update: Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities [Phase 2, Phase 3]
Summary
A Phase 2/3 trial evaluating a PCSK9 antibody in subjects with LDL receptor abnormalities (Homozygous Familial Hypercholesterolemia) has completed with results …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Homozygous Familial Hypercholesterolemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-10-02